ClinicalTrials.gg
Status unknownNCT04542447Updated Sep 10, 2020

To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.

A Phase 1 interventional study of Nuvastatic in Covid19, sponsored by Natureceuticals Sdn Bhd. Status unknown at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-09-10.

Sponsored by Natureceuticals Sdn Bhd · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies in COVID-19 with a site in India — 7 open to participants now, 9 under way, 4 of them phase 3. COVID-19 · India.

Planned enrollment
69th of 75
10 · median 272
Started
2020
with 52 others
Phase 1
4 of 113
none open now
Registered
40th of 113
by date

Among the 113 studies in COVID-19 with a site in India, this one is the 69th largest by planned enrollment of the 75 interventional ones that give a count, is one of 53 that started in 2020, is one of 4 in phase 1, and was the 40th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

7 of the 113 studies in COVID-19 with a site in India are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in COVID-19 with a site in India, or all of them as a file.
02

Study summary

A two arm open label multi-centered randomized interventional trial is proposed to assess aspects of safety and efficacy of Nuvastatic™ (Serial No: C5OSEW5050ESA) . Two parallel groups of (1:1) ratio comparing Nuvastatic™ versus standard care will be conducted on patients on oxygen saturation (SaO2) of 94% or less while they are breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) (PaO2:FiO2) at or below 300 mg Hg.

Primary Outcome Measures: time to clinical improvement, defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever comes first.

Secondary Outcome Measures: Clinical status as assessed with the seven-category ordinal scale on days 7 and 14, mortality at day 28.

  1. The duration of mechanical ventilation.
  2. The duration of hospitalization in survivors.
  3. The time (in days) from treatment initiation to death.
  4. Virologic measures included the proportions with viral RNA detection over time and viral RNA titer area under-curve (auc) measurements.
Read the detailed description

This study will propose Nuvastiatic™ as a new lead therapeutic agent for SARS-CoV-2, and new insights for currently ongoing clinical trials to treat SARS-CoV-2 infections. Nuvastatic™ could be used as potential anti-coronavirus therapy that acts on the human immune system or human cells as an immune modulator, and the other on coronavirus itself as an antiviral agent. In terms of the human immune system, the innate immune system response plays an important role in controlling the replication and infection of coronavirus, and interferon gamma, interleukins, Th cells, granulocyte macrophage are expected to enhance the immune response.

03

Conditions studied

  • Covid19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and nonpregnant female patients 18 years of age or older eligible if they had a diagnostic specimen that was positive on RT-PCR. -
  2. For Mild - Moderate cases: Subjects who show positive for nasal swab test at screening using RT-PCR protocol for Covid 19.
  3. For Severe cases - Has an oxygen saturation (Sao2) of 94% or less while they are breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) (Pao2:Fio2) at or below 300 mg Hg.
  4. Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant or breastfeeding.
  2. Patients who are allergic to this medicine
  3. Patients allergic to content of study product
  4. Patients with diabetes.
  5. Patients accompanied by serious physical diseases of heart, lung, brain, etc.
  6. Patients have any condition that in the judgement of the Investigators would make the subject inappropriate for entry into this study.
  7. Patients who are not able to take drugs orally.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Active comparator
    Nuvastatic + standard treatment

    5 patients, dosage: 3000 mg of Nuvastatic™ (C5OSEW5050ESA) each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.

    Drug: Nuvastatic

  • Placebo comparator
    Placebo

    5 patients, dosage: 3000 mg of placebo each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.

    Drug: Nuvastatic

Interventions

  • DrugNuvastatic

    Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy

    Also known as: C5OSEW5050ESA

06

What researchers measure

Primary outcomes

  1. To evaluate safety and efficacy Nuvastatic™ (C5OSEW5050ESA)

    Time to clinical improvement, defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever comes first.

    Time frame: 14 Days

  2. IL-6 reduction

    Improvement of Biomarkers: IL-6 reduction

    Time frame: 14 Days

  3. Serum c-reactive protein (CRP)

    Improvement of Biomarkers:key inflammatory markers Serum c-reactive protein (CRP)

    Time frame: 14 Days

  4. IgG

    Improvement of Biomarkers:key inflammatory markers IgG

    Time frame: 14 Days

  5. Hb

    Improvement of Biomarkers:key inflammatory markers Hb

    Time frame: 14 Days

  6. Total leucocyte count

    Improvement of Biomarkers:key inflammatory markers Total leucocyte count

    Time frame: 14 Days

  7. F2-Isoprostane

    Improvement of Biomarkers:key inflammatory markers urinary F2-Isoprostane.

    Time frame: 14 Days

  8. Improvement in ARDS associated clinical symptoms cause

    Role of VEGF as potential therapeutic target in acute respiratory distress syndrome (ARDS)

    Time frame: 14 Days

07

Study locations

1 of 1 sites recruiting
  • Navin Hospital
    Ghaziabad, Uttar Pradesh, India
    Recruiting
    • Dr Shruti Saini · Contact+919911757070
08

References and documents

Individual participant data

Plan to share: No — Institutional sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Sep 2020, 0 months after the start.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's planned 0 months is below that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2020
First posted
Sep 9, 2020
StartActual
Sep 1, 2020
Primary completionEst.
Sep 30, 2020
CompletionEst.
Sep 30, 2020
Last update
Sep 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04542447
Responsible party
Sponsor
First posted
Sep 9, 2020
Start date
Sep 1, 2020
Primary completion
Sep 30, 2020 (estimated)
Completion
Sep 30, 2020 (estimated)
Last update
Sep 10, 2020

Study contacts

Sanjay Vinaik
Contact
drsanjayvinaik@gmail.com
+91 0120-2777504
Sanjay Vinaik
principal investigator · Navin Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion